Search
Redhill Biopharma Ltd
RDHLAdd to Watchlist
0.812USD
-0.026-3.11%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
4.14MMarket Cap
LossP/E TTM
More Details of Redhill Biopharma Ltd Company
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Redhill Biopharma Ltd Info
Ticker SymbolRDHL
Company nameRedhill Biopharma Ltd
IPO dateFeb 01, 2011
CEOBen-Asher (Dror)
Number of employees35
Security typeDepository Receipt
Fiscal year-endFeb 01
Address21 Ha'arba'a St.
CityTEL AVIV-YAFO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code6473921
Phone97235413131
Websitehttps://www.redhillbio.com/
Ticker SymbolRDHL
IPO dateFeb 01, 2011
CEOBen-Asher (Dror)
Company Executives of Redhill Biopharma Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Rick D. Scruggs
Mr. Rick D. Scruggs
Chief Commercial Officer, Director
Chief Commercial Officer, Director
--
--
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
FAQs
Who are the top five shareholders of Redhill Biopharma Ltd?
The top five shareholders of Redhill Biopharma Ltd are: Mr. Dror Ben-Asher
How many institutions hold shares of Redhill Biopharma Ltd (RDHL)?
As of 2026Q1, 36 institutions hold shares of Redhill Biopharma Ltd, with a combined market value of approximately 504.44K, accounting for 9.72% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 347269.00.